Univo Pharmaceuticals (XTAE:UNVO-M) EV-to-EBIT : -1.39 (As of Jul. 07, 2025)

Univo Pharmaceuticals EV-to-EBIT Chart

Univo Pharmaceuticals Annual Data
	Trend	Dec13	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21
EV-to-EBIT		Get a 7-Day Free Trial				-19.36	-0.56	-5.31	14,521.11	-146.01

Univo Pharmaceuticals Quarterly Data
	Dec14	Dec15	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
EV-to-EBIT	Get a 7-Day Free Trial													21.54	26.56	-146.01	53.77	-2.22

Competitive Comparison of Univo Pharmaceuticals's EV-to-EBIT

For the Biotechnology subindustry, Univo Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Univo Pharmaceuticals's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Univo Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Univo Pharmaceuticals's EV-to-EBIT falls into.

Univo Pharmaceuticals EV-to-EBIT Calculation

Univo Pharmaceuticals's EV-to-EBIT for today is calculated as:

Univo Pharmaceuticals's current Enterprise Value is ₪40.32 Mil.
Univo Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was ₪-29.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Univo Pharmaceuticals  (XTAE:UNVO-M) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Univo Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2022 is calculated as:

Univo Pharmaceuticals's Enterprise Value for the quarter that ended in Jun. 2022 was ₪64.07 Mil.
Univo Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was ₪-29.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Univo Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Univo Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Univo Pharmaceuticals Business Description